Anoro Ellipta Dosage/Direction for Use

Pharmaceutical form: Inhalation powder, pre-dispensed.
Umeclidinium + Vilanterol (Anoro Ellipta) is for oral inhalation only.
Umeclidinium + Vilanterol (Anoro Ellipta) should be administered once daily at the same time each day.
Adults: The recommended and maximum dose is one inhalation of Umeclidinium + Vilanterol (Anoro Ellipta) 62.5/25 micrograms once daily.
Children: Use in patients less than 18 years of age is not relevant given the indication for this product.
Elderly: No dosage adjustment is required in patients over 65 years (see Pharmacology: Pharmacokinetics: Special Patient Populations under Actions).
Renal impairment: No dosage adjustment is required in patients with renal impairment (see Pharmacology: Pharmacokinetics: Special Patient Populations under Actions).
Hepatic impairment: No dosage adjustment is required in patients with mild or moderate hepatic impairment. Umeclidinium + Vilanterol (Anoro Ellipta) has not been studied in patients with severe hepatic impairment (see Pharmacology: Pharmacokinetics: Special Patient Populations under Actions).